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Abstract
Tumor necrosis factor-alpha (TNF-a) is a potent proinflammatory cytokine that inhibits osteoblast differentiation while
stimulating osteoclast differentiation and bone resorption. TNF-a activates MAP kinase pathway leading to inhibition of
osterix (Osx) expression. TNF-a also induces the expression of E3 ubiquitin ligase protein Smurf1 and Smurf2 and promotes
degradation of Runx2, another key transcription factor regulating osteoblast differentiation and bone formation. We
showed previously that overexpression of glucocorticoid (GC)-induced leucine zipper (GILZ) enhances osteogenic
differentiation of bone marrow mesenchymal stem cells (MSCs). We and others also showed that GILZ is a GC effecter and
mediates GC anti-inflammatory activity. In this study, we asked the question whether GILZ retains its osteogenic activity
while functioning as an anti-inflammatory mediator. To address this question, we infected mouse bone marrow MSCs with
retroviruses expressing GILZ and induced them for osteogenic differentiation in the presence or absence of TNF-a. Our
results show that overexpression of GILZ antagonized the inhibitory effects of TNF-a on MSC osteogenic differentiation and
the mRNA and protein expression of Osx and Runx2, two pivotal osteogenic regulators. Further studies show that these
antagonistic actions occur via mechanisms involving GILZ inhibition of TNF-a-induced ERK MAP kinase activation and
protein degradation. These results suggest that GILZ may have therapeutic potential as a novel anti-inflammation therapy.
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Introduction
Chronic inflammation, such as rheumatoid arthritis (RA),
causes bone loss. Long-term use of steroid hormone glucocorti-
coids (GCs), which are potent anti-inflammatory agents and are
frequently used to treat these conditions, also causes bone loss and
results in osteoporosis (GC-induced osteoporosis), and is thus a
major limiting factor for long term GC therapy [1,2]. Despite
intensive investigations, the molecular mechanisms underlying GC
anti-inflammatory actions and GC-induced bone loss are still not
clear.
Bone marrow mesenchymal stem cells (MSCs) are multipotent
cells and can differentiate into several distinct cell lineages,
including bone-forming osteoblasts and cartilage-forming chon-
drocytes [3]. Several recent studies have reported that MSCs are
present in cultures of RA synovial fluid or tissue [4–7]. These
MSCs are believed to be recruited to the arthritic joints but, due to
the inflammation, their normal differentiation is arrested and play
an important role in the pathogenesis of RA [8].
The osteogenic differentiation of MSC is controlled by two
key transcription factors, osterix (Osx) and Runx2 [9,10]. The
expression of Osx and Runx2 are regulated by many factors
such as hormones/growth factors and cytokines including tumor
necrosis factor-alpha (TNF-a), one of the major proinflammatory
cytokines whose production is elevated in arthritic joints and
causes inflammation, cartilage destruction, and bone erosion
[11,12]. Transgenic mice overexpressing TNF-a are severely
osteoporotic [13], and blockade of TNF-a by its soluble receptor
(Etanercept) effectively reduces the inflammatory response.
Studies have shown that key mechanisms by which TNF-a
inhibits Osx and Runx2 include activation of the mitogen-
activated protein kinase (MAPK) pathway and induction of the
E3 ubiquitin ligase Smurf proteins. Activation of ERK MAP
kinase by TNF-a results in inhibition of Osx transcription [14],
and induction of Smurf1 and Smurf2 results in accelerated
Runx2 protein degradation through the proteasomal degradation
pathway [15–17].
Glucocorticoid-induced leucine zipper (GILZ) is a member of
the leucine zipper protein family and belongs to the transforming
growth factor b-stimulated clone-22 (TSC-22d3) family of
transcription factors [18]. GILZ can physically interact with and
inhibit the activities of the key inflammatory signaling mediators
NF-kB and AP-1 [19,20]. GILZ also interacts with MAP kinase
family members Ras and Raf, resulting in inhibition of Raf-1
phosphorylation and, subsequently, inhibition of ERK1/2 phos-
phorylation and AP-1-dependent transcription [21,22].
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e31717We reported previously that overexpression of GILZ in bone
marrow MSCs enhances osteogenic differentiation by shifting
MSC lineage commitment towards the osteoblast pathway [23].
We also showed that GILZ is a GC effect mediator and inhibits
TNF-a-induced cyclooxygenase-2 (Cox-2) expression by blocking
TNF-a-induced NF-kB nuclear translocation [24]. In this report
we show that GILZ antagonizes the inhibitory effect of TNF-a on
MSC osteogenic differentiation and provide a possible mechanism
by which it does so. Since GILZ is an anti-inflammatory molecule
and pro-osteogenic, this study suggests that GILZ could be an
ideal drug candidate for a new anti-inflammatory therapy.
Results
Overexpression of GILZ antagonizes the inhibitory effect
of TNF-a on MSC osteogenic differentiation
To investigate whether GILZ is capable of enhancing MSC
osteogenic differentiation while serving as an anti-inflammatory
mediator, we infected MSCs with retroviruses expressing GILZ or
GFP (MSC-GILZ and MSC-GFP, respectively) and induced them
with osteogenic induction media (OS) in the absence or presence
of different concentrations of TNF-a. Results show that in the
absence of TNF-a, both MSC-GILZ and MSC-GFP cells
differentiated normally and formed mineralized bone nodules
after 21 days of culture as indicated by alizarin red S (ARS)
staining (Fig. 1A, first row). In the presence of TNF-a, however,
mineralization of MSC-GFP control cells was inhibited in a TNF-
a dose-dependent manner (Fig. 1A, second and third rows). In
contrast, this inhibition was largely prevented in MSC-GILZ cells.
Same result was obtained by alkaline phosphatase (ALP) staining
of a shorter term (8 days) culture under the same conditions
(Fig. 1C). Higher concentrations of TNF-a (.3 ng/ml) cause the
death of both MSC-GILZ and MSC-GFP cells in long-term
culture. Consistent to our previous studies, MSC-GILZ cells
always showed a significantly higher degree of mineralization than
the MSC-GFP cells (Fig. 1A, first row) [23]. Quantitative results of
Fig. 1A and C are shown as bar graphs in Fig. 1B and D,
respectively. Because dexamethasone, which induces endogenous
GILZ, was not supplemented in our osteogenic induction media,
these results demonstrate that the anti-TNF-a effect observed here
was due to the overexpression of GILZ.
GILZ antagonizes TNF-a inhibition of osterix (Osx) and
Runx2
To elucidate the molecular mechanisms underlying GILZ
antagonizing TNF-a inhibition of osteoblast differentiation, we
examined the expression levels of Osx and Runx2 mRNA and
protein. MSC-GFP and MSC-GILZ cells were cultured in OS in
the absence or presence of TNF-a (1 ng/ml). Eight days after the
treatment, one set of cells was harvested for RNA analysis and the
other set for protein analysis. Results show that in the absence of
TNF-a, levels of Osx and Runx2 mRNA (Fig. 2A, B) and protein
(Fig. 2C–E) were induced significantly in both GFP- and GILZ-
expressing cells. TNF-a treatment reduced the levels of Osx and
Runx2 in both MSC-GFP and MSC-GILZ cells. However,
compared with MSC-GFP cells, the levels of Osx and Runx2
mRNA and protein were still significantly higher in MSC-GILZ
cells.
GILZ inhibits TNF-a-induced ERK phosphorylation and
Smurf expression
To determine whether the protection of Osx by GILZ (Fig. 2)
was due to the inhibition of TNF-a-induced ERK/MAP kinase
activity, we treated cells with TNF-a (1 ng/ml, 15 min) and
examined the status of ERK phosphorylation using an antibody
specific to phosphorylated ERK. Results show that TNF-a
treatment induced ERK1/2 phosphorylation in both MSC-GFP
and MSC-GILZ cells; however, this induction was reduced
significantly in MSC-GILZ cells (Fig. 3A, compare lane 4 to lane
2). GILZ seems to have no significant effect on basal levels of
ERK1/2 phosphorylation (compare lane 1 to lane 3, and the
quantitative results in Fig. 3B). Levels of total ERK were detected
by antibodies against ERK. Equal loading of lanes is shown by
levels of a-tubulin. Together, these results demonstrated that
overexpression of GILZ can inhibit TNF-a-induced ERK/MAP
kinase activation, and suggest that GILZ antagonizes TNF-a
inhibition of Osx, in part, by inhibiting ERK1/2 phosphorylation.
Next, we examined the levels of E3 ubiquitin ligases Smurf1 and
Smurf2 since studies have shown that TNF-a up-regulates Smurf1
and Smurf2, which, in turn, promotes Runx2 protein degradation
[15,16]. The same RNA samples collected from cells treated with
TNF-a for analysis of Osx and Runx2 mRNA described above
(Fig. 2) were used. Results show that overexpression of GILZ
(MSC-GILZ) reduced TNF-a-induced Smurf1 and Smurf2
expression at both mRNA (Fig. 3C, D) and protein (Fig. 3E–G)
levels.
Effect of GILZ on Osx promoter activity
Since GILZ antagonizes TNF-a-induced ERK phosphorylation
(Fig. 3), an event through which TNF-a regulates Osx expression,
we next examined whether this antagonism occurs at the
transcriptional level. A 791-nucleotide fragment of the Osx
promoter region (2700 to +91 relative to the transcription start
site) was PCR amplified from mouse genomic DNA and inserted
into a luciferase reporter vector (pGL3-basic, see details in
Methods). This reporter construct, referred to as Osx-Luc, was
transfected into C3H10T1/2 cells. The transfected cells were
treated with TNF-a or different kinase inhibitors separately, or
TNF-a plus an inhibitor, to determine which kinase pathway is
primarily responsible for TNF-a-mediated inhibition of Osx. As
with the mRNA and protein expression profiles, TNF-a reduced
basal level of Osx-Luc reporter activity significantly (Fig. 4A,
compare column 2 with column 1). Treatment of cell with
PD98059 (ERK inhibitor) significantly increased Osx-Luc reporter
activity (compare column 3 with column 1) and neutralized TNF-a
inhibition on this reporter activity (compare column 6 with
columns 1 and 2). In contrast, SP600125 (JNK inhibitor) or
SB203580 (p38 inhibitor) had no such an effect (compare columns
4 and 5 with column 1; columns 7 and 8 with column 2). These
results demonstrated that TNF-a inhibits Osx promoter transcrip-
tional activity through activating ERK/MAP kinase pathway, but
not JNK or p38 pathway. To determine the role of GILZ in ERK
phoshorylation, and subsequently, Osx transcription, we co-
transfected C3H10T1/2 cells with Osx-Luc reporter and a GILZ
expression plasmid. Results show that overexpression of GILZ,
which, by itself enhanced Osx-Luc basal promoter activity (Fig. 4B,
compare column 3 with column 1), counteracted TNF-a inhi-
bitory effect and rescued the promoter activity almost to its base
level (compare column 4 with columns 1 and 2). Treatment of cells
with PD98059 offset completely the TNF-a effect and restored
Osx-Luc promoter activity to its basal level (compare column 6
with columns 1 and 2), but overexpression of GILZ did not
synergize or enhance PD98059 effect (compare column 5 with
column 3). These results demonstrated that the antagonistic effect
of GILZ on TNF-a inhibition of Osx is fulfilled, in part, through
GILZ inhibition of TNF-a-induced ERK1/2 phosphorylation.
This conclusion is further supported by the changes of Osx mRNA
GILZ Antagonizes TNF-a Action
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which showed that PD98059 rescues TNF-a-mediated inhibition
of Osx mRNA expression (Fig. 4C).
Discussion
In this study we have demonstrated that GILZ antagonizes the
inhibitory effect of TNF-a on MSC osteogenic differentiation.
Evidence presented in this study showed that GILZ antagonizes
TNF-a effect in osteoblast differentiation by inhibiting TNF-a-
induced ERK/MAP kinase activation and by inhibiting the
expression of E3 ubiquitin ligase Smurf proteins. This antagonistic
effect resulted in a partial rescue of TNF-a inhibition on Osx
transcription, and a deceleration of TNF-a-induced Runx2
degradation. Attempts to confirm these results by knocking down
GILZ were proven to be unsuccessful due to the low basal levels of
endogenous GILZ expression (barely detectable by Western blot),
and approaches that can increase GILZ levels, such as treatment
of cells with glucocorticoid, activates glucocorticoid receptor and
induces the expression of MAP kinase phosphatase-1 (MKP-1)
[25], which inhibits ERK phosphorylation and compensates GILZ
knockdown effect. We think that the pro-osteogenic effect of GILZ
is overridden by the glucocorticoid receptor in the continued
glucocorticoid presence and that the adverse bone effect of
glucocorticoids is mediated primarily by glucocorticoid receptor.
Supporting this notion, a recent in vivo study showed that mice with
bone-specific glucocorticoid receptor knockout resist to glucocor-
ticoid-induced bone loss [26]. Indeed, continuous dexamethasone
treatment, which activates glucocorticoid receptor constantly,
reduces mineralized bone nodule formation (Figure S1). We think
that our current system is inadequate for testing GILZ knockdown
effect. A better experimental system, such as knockdown GILZ in
glucocorticoid receptor knockout or MKP-1 knockout MSCs,
should be appropriate for addressing this issue.
Osx and Runx2 are pivotal transcription factors regulating
osteogenic differentiation and bone formation. These two genes
are primary targets for TNF-a in osteoblasts. In addition to
activating the ERK pathway, TNF-a also activates NF-kB and
induces p65/NF-kB nuclear translocation [19,24]. However,
elegant experiments carried out in the Nanes laboratory have
demonstrated that the inhibition of Osx by TNF-a does not
involve the NF-kB pathway, although TNF-a induced p65 nuclear
entry and TNF-response element is present in the Osx promoter
region [14]. In fact, forced overexpression of NF-kB activated Osx
promoter activity (in vitro luciferase reporter assays) [14]. Since NF-
kB pathway does not play a major role in TNF-a-mediated
inhibition of Osx, and our previous studies have shown that GILZ
inhibits TNF-a-induced p65/NF-kB nuclear translocation in
Figure 1. Effect of GILZ on TNF-a inhibition of MSC osteogenic differentiation. MSC-GFP and MSC-GILZ cells were cultured in osteogenic
induction media (OS) in the absence or presence of indicated concentrations of TNF-a. (A) Cells were stained with alizarin red S on day 21 to visualize
mineralized bone matrix. (B) Bar graph showing quantitative results of A. After scanning, the plates were destained with a solution containing 10%
cetylpyridinium chloride in sodium phosphate. Concentrations of recovered ARS dye were determined by absorbance measurement and presented
as fold changes relative to the OD value of MSC-GFP cells cultured in OS media. Each bar represents an average of 15 wells from 3 independent
plates. (C) MSC-GFP and MSC-GILZ cells were cultured as above (A) for 8 days and stained for ALP to detect surface ALP-positive cell populations. (D)
Bar graph showing quantitative results of C. Intensities of scanned images were analyzed with NIH Image J software and presented as fold changes
relative to the value of MSC-GFP cells cultured in OS media. Each bar represents an average of 15 wells from 3 independent plates. Representative
scanned images are shown. Error bars indicate S.D. a, p,0.01.
doi:10.1371/journal.pone.0031717.g001
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because these studies were conducted in the same experimental
system.
The inhibition of Runx2 by TNF-a, on the other hand, is
primarily post-translational, involving TNF-a up-regulation of
Smurf proteins and resulting in accelerated Runx2 protein
degradation [16,17]. A perfect AP-1 motif is found in the Runx2
promoter region. Although other AP-1 members, i.e., Fra2 and
JunD, can bind to this site, c-Jun and c-Fos, with which GILZ
interacts, showed no binding activity [27]. These published studies
demonstrated that the accelerated Runx2 protein degradation,
which is triggered by TNF-a induction of Smurf expression, is a
key mechanism by which TNF-a regulates Runx2 activity. NF-kB
seems to involve only in the inhibition of BMP signaling by TNF-
a. Activation of NF-kB results in disruption of BMP-induced
Smad DNA-binding activity [28].
Although the causes of rheumatoid arthritis (RA), which is
characterized by inflammation, pain, and swelling [11], are still
not clear, the levels of proinflammatory cytokines (i.e., TNF-a, IL-
1b) and inducible enzymes involved in inflammation (i.e., COX-2)
Figure 2. Effect of GILZ on TNF-a regulation of Osx and Runx2 expression. Real-time qRT-PCR and Western blot analyses of mRNA and
protein expression. MSC-GFP and MSC-GILZ cells were cultured in OS with or without 1 ng/ml TNF-a (OST) for 8 days. At the end of treatment, one set
of cells was harvested for real-time qRT-PCR (A, B) and a second set for Western blot (C) analyses of Osx and Runx2. Equal loading of samples in each
lane is shown by the levels of b-actin. These experiments were performed at least three times with similar results. Quantitative results for levels of Osx
and Runx2 protein are presented as bar graphs (D, E). Value of intensity for MSC-GFP cells cultured in regular DMEM growth medium (GM) is
arbitrarily set as 1. Error bars indicate S.D. a, p,0.01 (n=3).
doi:10.1371/journal.pone.0031717.g002
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inhibition of these inflammatory molecules, for example, by using
TNF-a blocker (Etanercept) and COX-2 selective inhibitors
(Coxibs), has been a common clinical practice. Glucocorticoids
are among the best known anti-inflammatory agents and have
been widely used in the clinic for treating RA [29–32]. However,
long-term glucocorticoid therapy causes many side effects,
including osteoporosis. This significant clinical problem was
recognized almost the same time that glucocorticoids were
introduced into the clinic nearly 60 years ago, and it has been a
major factor for limiting long-term glucocorticoid therapy. Recent
studies in our laboratory have shown that overexpression of GILZ
enhances MSC osteogenic differentiation [23] and inhibits TNF-
a-induced COX-2 expression [24]. Studies from other laboratories
Figure 3. Effect of GILZ on TNF-a-induced ERK phosphorylation and Smurf expression. (A, B) MSC-GFP and MSC-GILZ cells were serum
starved for 48 hr and then treated with TNF-a (1 ng/ml) for 15 min before harvesting. Equal amounts of total cell lysates were separated on SDS PAGE
gel, transferred onto membrane and analyzed for levels of phosphorylated ERK1/2 (pERK). Levels of pERK were quantified with NIH Image J software
and presented as a ratio of pERK/total ERK in B. Value from untreated MSC-GFP is arbitrarily set as 1. Experiments were repeated three times with
similar results. Levels of overexpressed GILZ are also shown. Error bars indicate SD. a-tubulin, instead of b-actin, was used as a loading control in these
experiments because b-actin and ERK have similar molecular weights. (C–F) RNA and protein samples from MSC-GFP and MSC-GILZ cells used in the
experiments described in figure 2 were analyzed by real-time qRT-PCR and Western blot to show the levels of Smurf1 and Smurf 2 mRNA (C, D) and
protein (E). Quantitative results of Fig. 3E are shown as bar graphs in Fig. 3F and G, respectively. Data were normalized to b-actin and expressed as
fold changes relative to control cells cultured in GM. These experiments were repeated three times with similar results. Error bars indicate SD. a,
p,0.01 (n=3).
doi:10.1371/journal.pone.0031717.g003
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inflammatory action mediator [33–35]. Importantly, a recent in vivo
studybyBeaulieu etal showed thatthelevelsof GILZisincreasedby
therapeutic doses of glucocorticoids in the synovium of collagen-
induced arthritis (CIA) mice, and that knockdown of GILZ using
siRNA increases the clinical and histologic severity of CIA and
synovial expression of TNF-a and IL-1 [36]. This in vivo study
directly supports our findings reported here regarding the role
and therapeutic potential of GILZ in RA. TNF-a is a potent
proinflammatory cytokine and triggers inflammatory reactions and
further amplifies inflammatory signals by inducing other inflamma-
tory cytokines (e.g., IL-1b, IL-6), chemokines (e.g., MIP-1a,M C P 1 ) ,
and inducible enzymes (e.g., COX-2, iNOS). Importantly, TNF-a
inhibits genes that directly regulate osteoblast differentiation and
bone formation [14–16,37]. Thus, approachesthat can inhibitTNF-
a activity (production or action) would have therapeutic potential for
preventing bone loss. Evidence that GILZ not only mediates
glucocorticoid anti-inflammatory action, but also enhances MSC
osteogenic differentiation suggests that GILZ is a prominent anti-
inflammatory drug candidate that could be safe to bone.
Materials and Methods
Reagents and chemicals
TNF-a (#410-MT) was purchased from R&D Systems Inc.;
PD98059 (#PHZ1164) from BioSource International, Inc.; One-
Step NBT/BCIP solution (#34042) from Pierce; SYBR Green
PCR Master Mix (#4367659) from Applied Biosystems; Osx
antibody (#ab22552) from Abcam Inc.; Runx2 (#130-3)
monoclonal antibody from MBL International; Smurf1
(#AP2104a) and Smurf2 (#AP2105a) antibodies from Abgent
Inc.; ERK1/2 (#9102) and phospho-ERK1/2 (#9106) antibodies
from Cell Signaling Technology, Inc. All chemicals, except where
specified, were purchased from Sigma-Aldrich.
Figure 4. Effect of GILZ on TNF-a regulation of Osx transcription. (A, B) Transient transfection and luciferase-reporter assays. (A) C3H10T1/2
cells were transfected with Osx-Luc promoter reporter and treated either with TNF-a (10 ng/ml) or an indicated kinase inhibitor alone, or with TNF-a
plus an inhibitor for 24 hr and then harvested for luciferase assays. The concentration of TNF-a used in this experiment is based on the study by Lu
et al [14] as the promoter reporter construct is same. (B) C3H10T1/2 cells were cotransfected with Osx-Luc reporter and a GILZ expression plasmid
and treated with TNF-a and ERK inhibitor PD98059 as indicated. Luciferase activity was measured as in A. these experiments were performed 3 times
in triplicate. (C) Real-time qRT-PCR analysis. MSCs were first cultured in OS medium for 5 days (to initiate the osteogenic differentiation program) and
then were treated continuously with PD98059 for 17 hr, or treated with PD98059 for 5 hr prior to TNF-a (0.5 or 2 ng/ml, T.5 and T2, respectively)
treatment for 12 hr before harvesting for RNA isolation and qRT-PCR analysis. Data were normalized to b-actin and expressed as fold changes relative
to the mRNA level of untreated (GM) Cells. Experiments were performed 2 times in duplicates with the same results. Error bars indicate SD. a, p,0.01
(n=2).
doi:10.1371/journal.pone.0031717.g004
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Isolation, characterization and infection of MSCs were described
previously [23,24,38]. Briefly, MSCs were isolated from 18-month-
old male C57BL/6 mice using a negative immuno-depletion (using
magnetic beads conjugated with anti-mouse CD11b, CD45R/
B220,andPanDC)and positiveimmuno-selection(usinganti-Sca-1
beads) approach with an animal procedure approved by the
Institutional Animal Care and Use Committee (IACUC) at the
Georgia Health Sciences University (Approval #: BR08-10-108).
For GILZ overexpression, the MSCswereinfected with retroviruses
expressing GILZ (MSC-GILZ) or GFP (MSC-GFP, as a control).
The viral infection efficiency (.90%) and levels of GILZ expression
in the infected cells were confirmed by Western blot and
immunofluorescence microscopy as previously described [23,24].
Osteogenic differentiation
Cells were plated in 96-well plates in triplicate at a density of
1610
4 cells/cm
2 the previous day and then treated with osteo-
genic supplements (OS) consisting of DMEM supplemented with
2% FBS, 5 mM b-glycerophosphate, and 50 mM L-ascorbic acid-
2-phosphate for the indicated time period.
For alkaline phosphatase (ALP) staining, cells were rinsed 3
times with calcium and phosphate-free saline solution, fixed in 4%
paraformaldehyde for 30 min at RT, washed 3 times with double-
distilled water, and stained with One-Step
TM NBT/BCIP solution
(Pierce, Rockford, IL) for 15 min at RT. Cells were washed again
with double-distilled water and the plates were scanned using a
CanoScan LiDE 80 flat-bed scanner.
For alizarin red S (ARS) staining, cells were rinsed with calcium
and phosphate-free saline solution, and fixed with ice-cold 70%
ethanol for 1 hr. After a brief wash with water, cells were stained
for 10 min with 40 mM ARS solution (pH 4.2) at room
temperature. Cells were rinsed five times with water followed by
a 15-min wash with PBS (with rotation) to reduce nonspecific ARS
staining. After scanning of the plate for digital images, ARS dye
was dissolved in 10% cetylpyridinium chloride (CPC) in 10 mM
sodium phosphate (pH 7.0) for 15 min at RT and the concentra-
tions of ARS determined by absorbance measurement as
previously described [23].
Western blot analysis
Cells were cultured in osteogenic induction media in the
presence of TNF-a (1 ng/ml) for 8 days before they were
harvested. Equal amounts of total protein were separated on
SDS-PAGE and analyzed by Western blot as previously described
[23,24] using the indicated antibodies.
RNA extraction and real-time qRT-PCR
Total cellular RNA was isolated using TRIzol reagent
according to the manufacturer’s instructions (Invitrogen Corp.).
Equal amounts of total RNA (2 mg) were reverse transcribed using
TaqMan Reverse Transcription Reagents (Applied Biosystems),
and the mRNA levels of the indicated genes were analyzed in
triplicate using SYBR Green Master Mix and a Chromo-4 real-
time RT-PCR instrument (MJ Research). The mRNA levels were
normalized to b-actin (internal control) and gene expression was
presented as fold changes. The primer sequences used in the PCR
reactions are listed in Table 1.
Construction of Osx promoter-luciferase reporter
(Osx-Luc)
A 791-nucleotide promoter sequence corresponding to 2700 to
+91 regionof the Osx gene was PCRamplifiedfrommouse genomic
DNA. The primer sequences used in PCR amplification are: 59-
ATAGCGGTACCTTGTTCCTTTTCCCTCCTGTTC-39 (for-
ward), and 59- GTATCAAGCTTCTGGGGACCGGGTCC-
CAAG -39 (reverse). A Kpn I and a Hind III restriction site
(underlined) were included in the forward and reverse primers,
respectively. The resulting PCR product was digested with Kpn I
and Hind III and inserted into the corresponding cloning sites in
the pGL3 Basic luciferase reporter vector (Promega, Madison,
WI).
Transient transfection and luciferase assays
Osx-Luc was cotransfected with the indicated amounts of
expression vectors and an internal control plasmid (pRL-null) into
C3H10T1/2 cells using Lipofectamine Plus reagents (Invitrogen
Corp.). Total amount of DNA in each transfection was kept
constant by adding empty vector DNA (pcDNA3). Twenty-four
hours after transfection, the cells were lysed and luciferase activity
measured with separate substrates to detect the luciferase (firefly)
in the pGL3-basic plasmid and to the second luciferase (Renilla)
encoded by the pRL-null vector (dual luciferase assay kit,
Promega) as previously described [24]. Luciferase values were
normalized to Renilla luciferase to correct variations in transfection
efficiency.
Statistics analysis
Data were analyzed with InStat Software (version 3.06,
GraphPad Software Inc.) using one-way analysis of variance
(ANOVA) followed by Bonferroni multiple comparison test. A p
value less than 0.05 (p,0.05) was considered to be statistically
significant. Fold differences are indicated and are presented as
mean 6 SD.
Supporting Information
Figure S1 Continuous glucocorticoid treatment inhibits
MSC osteogenic differentiation. MSC-GFP and MSC-GILZ
cells were cultured in OS without or with 100 nM dexamethasone
Table 1. Primer sequences.
Genes GenBank # Forward (59-39) Reverse (59-39) Size (bp)
Osterix NM_130458 ACCAGGTCCAGGCAACAC GCAGTCGCAGGTAGAACG 373
Runx2 NM_009820 CCACCACTCACTACCACACG TCAGCGTCAACACCATCATT 250
Smurf1 NM_029438 AGTTCGTGGCCAAATAGTGG GTTCCTTCGTTCTCCAGCAG 99
Smurf2 NM_025481 GTGAAGAGCTCGGTCCTTTG AGAGCCGGGGATCTGTAAAT 114
b-actin NM_007393 CTGGCACCACACCTTCTACA GGTACGACCAGAGGCATACA 190
doi:10.1371/journal.pone.0031717.t001
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without Dex for the remaining days indicated. Cells were stained
with ARS on day 22.
(TIF)
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